THE VEGF AND BMP-2 LEVELS IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND THE RELATIONSHIP TO TREATMENT WITH TUMOUR NECROSIS FACTOR ALPHA INHIBITORS

Marian Tošovský¹, Petr Bradna¹, Ctirad Andrýs², Kateřina Andrýsová¹, Eva Čermáková⁴, Tomáš Soukup¹

Charles University in Prague, Faculty of Medicine in Hradec Králové, and University Hospital Hradec Králové, Czech Republic¹: 2nd Internal Gastroenterological Department¹, Institute of Clinical Immunology and Allergology², Institute of Medical Biophysics⁴

Summary: Introduction: Ankylosing spondylitis (AS) is an inflammatory rheumatic disease characterized by the development of osteoprotective changes in the spine which could possibly result in ankylosis. Treatment with tumour necrosis factor alpha (TNFα) inhibitors has proved to be an important step forward in the treatment of this disease, but for the time being it is not clear whether it favourably influences radiographic progression of the disease. Vascular endothelial growth factor most probably plays a role in the development of osteoprotective changes and recently its predictive influence on radiographic progression has been demonstrated. Bone morphogenic protein 2 (BMP-2) participates in the regulation of bone proliferation and its increased serum level has been demonstrated in patients with advanced AS and correlated with the degree of radiographic changes. Aim: The study aims to evaluate the VEGF and BMP-2 levels in patients with ankylosing spondylitis and how these levels relate to the concurrent treatment with TNFα inhibitors. Methods: Sera were evaluated from patients at the Rheumatologic Clinic of the Hradec Králové Faculty Hospital who fulfilled the modified New York Criteria for AS (n = 55). In these patients, the parameters of the activity of the disease (BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, CRP = C-reactive protein) and the concurrent therapy (TNFα inhibitors, n = 21, vs. non-anti TNFα, n = 34) were recorded. The levels of VEGF and BMP-2 were analyzed using the ELISA method. Results: In patients treated with TNFα inhibitors, a significantly lower VEGF level was found when compared to untreated patients (140.3 (109.4; 262.2) vs. 261 (172.4; 396.6) pg/ml; p = 0.02). No difference was found between BMP-2 levels in both groups (treated vs. untreated patients) (254.8 (230.1; 267.3) vs. 261.1 (248.6; 273.5) pg/ml; p = 0.24). A correlation analysis did not reveal any relationship between VEGF and BMP-2 (r = 0.057; p = 0.68). Serum levels of VEGF correlated with serum levels of CRP (r = 0.56; p = 0.00001) and the BASDAI value (r = 0.33; p = 0.015). Conclusion: Significantly lower VEGF levels were found in patients treated with TNFα inhibitors versus the untreated patients. These findings are in harmony with some hitherto published analyses and may give evidence of a favourable effect of TNFα inhibitors on radiographic progression. Neither influence on the BMP-2 level by treatment with TNFα inhibitors nor correlation with VEGF levels was demonstrated.

Key words: Ankylosing spondylitis; Axial spondyloarthritis; Vascular endothelial growth factor; Bone morphogenic factor 2; Radiographic progression

Ankylosing spondylitis (AS) is an inflammatory rheumatic disease which causes a number of difficulties in the musculoskeletal system. A typical manifestation in the axial skeleton is inflammatory back pain which is typically at its worse in the early morning and disappears or subsides after limbering up. The cause of the pain is supposed to be the inflammatory changes in the region of vertebral corners (bone swelling, bone marrow oedema), which magnetic resonance imaging (MRI) can reveal as an increased signal in the STIR (short tau inversion recovery) sequences (1). The relationship between the extent of changes in MR and the degree of infiltration of inflammatory cells was demonstrated by histopathological analysis in biptic samples of sacro-iliac joints (2). Another feature is the development of osteoprotective changes in the longitudinal ligaments (syndesmophytes), which may result in complete spinal ankylosis.

In recent years there has been marked progress in the treatment of AS due to the appearance of the inhibitors of tumour-necrosis factor alpha (TNFα). The treatment results in the apparent alleviation of pain and a decrease in inflammatory parameters in serum, and concurrently an effect on the disappearance of changes in MR (swelling of vertebral corners, bone marrow oedema) was demonstrated (1). Nevertheless, the opinions are not hitherto unequivocal whether the TNFα inhibitors influence radiographic progression (the development of new or deterioration of the existing radiographic changes in the spine typical of AS).
The first two-year studies with TNFα inhibitors did not demonstrate a favourable effect on radiographic progression (3, 4, 5). In addition, these data were supported by some experiments on animal models. For example, DBA/1 mice (mice with peripheral arthritis resulting in joint ankylosis) were used as a model of spondyloarthritis, in which the treatment with TNFα inhibitors (etanercept) did not result in the prevention of joint ankylosis (6). It contributed to the opinion that inflammation and osteoplastic changes take place independently of each other.

Some more recent data suggest that osteoplastic changes in ankylosing spondylitis develop as independent reparative processes in the sites where the inflammatory changes (“early lesions”) reached the limits of irreversible changes (“advanced lesions”) (7). Early lesions were defined by an increased signal on STIR MR sequences; an advanced lesion is indicated by a decrease in the increased signal in STIR sequences from the apex of the vertebral corner and changes in T1 weighed scans in this localization (erosion, sclerotication, fat infiltration). By the action of various regulatory mechanisms there then develops proliferation of the bone, which then may take place independently of the presence or absence of inflammation. New syndesmophytes have been demonstrated to develop unequivocally more often in the sites of these “advanced lesions” (7).

It is assumed that vascular proliferation and vascular endothelial growth factor (VEGF) (due to its regulatory role) participate in the development of advanced lesions as well. Increased serum level of VEGF was demonstrated in patients with AS (8) and correlated with the activity of the disease (BASDAI, C-reactive protein) (9). A predictive effect of the serum level of VEGF on radiographic progression was also recently demonstrated (10). The present paper aims at comparing the serum levels of VEGF in patients with AS in relationship to ongoing treatment with TNFα inhibitors. Another aim is to compare the BMP-2 (bone morphogenic protein) levels in patients treated and not treated with TNFα inhibitors and to examine the relationship between VEGF and BMP-2. BMP-2 participates in the regulation of bone proliferation and both its increased serum level in patients suffering from advanced AS and a positive correlation with the degree of radiographic changes were demonstrated (11).

Material and Methods

The analysis used the sera evaluated from patients at the Rheumatologic Clinic of the Hradec Králové Faculty Hospital who fulfilled the modified New York Criteria for AS (n = 55) (12). At the time of blood withdrawal, parameters of the activity of the disease (BASDAI = Bath Ankylosing Spondylitis Disease Activity Index (13), CRP = C-reactive protein) and the ongoing therapy (TNFα inhibitors, n = 21, vs. non-anti TNFα, n = 34) were recorded. The VEGF level was analyzed by means of the ELISA (enzyme linked immunosorbent assay) method with the use of a commercial Quantikine Human VEGF Immunoassay kit, R&D Systems, Inc., USA. The BMP-2 level was also measured by means of the ELISA method using a BMP2 Human ELISA Kit, Abcam (UK). The levels of C-reactive protein (CRP) were assayed immunoturbidimetrically on a Modular analyzer (Roche, Switzerland) using the diagnostic agents of the same firm.

The values of the parameters were presented by the median and 95% confidence interval for the median. A box diagram was employed for graphic presentation. Differences between the groups were evaluated using double-selection t-test, or nonparametric Mann-Whitney, Kolmogorov-Smirnov tests. Spearman coefficient of rank correlation was employed to evaluate the relations of the parameters. The selected level of significance was α = 0.05.

Informed consent was obtained. The study was carried out according to the Declaration of Helsinki. The procedures were approved by the local ethics committee.

Results

The principal characteristics of the cohort are summarized in Table 1. The median age of patients treated with TNF inhibitors (n = 21) vs. those untreated (n = 34) was 42 (37, 46) vs. 47.5 (38, 57) years and no statistically significant difference between the groups was found (p = 0.06). The representation of males in both groups was 85.7% (18/21) and 82.4% (28/34), respectively. The length of duration of disease was similar in both groups (median 13 and 17 years, respectively, p = 0.08). No difference was found between both groups in the values of serum level of CRP (3.2 (0.6; 6.1) vs. 4.95 (2.7; 6.8) mg/l; p = 0.24). The BASDAI value was significantly lower in patients treated with TNFα inhibitors (20.0 (10.6; 27.0) vs. 35.8 (24.0; 43.6); p = 0.00047). The median length of the treatment with TNFα inhibitors was 40 (9; 59) months. The representation of the individual preparations is shown in Table 2.

**Tab. 1: Characteristics of patients cohorts (CRP=C-reactive protein, BASDAI = Bath ankylosing spondylitis disease activity index).**

<table>
<thead>
<tr>
<th></th>
<th>TNFα</th>
<th>non TNFα</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>age, median (mean)</td>
<td>42 (42.8)</td>
<td>47.5 (49.4)</td>
<td>0.06</td>
</tr>
<tr>
<td>% incidence of men</td>
<td>85.7 (18/21)</td>
<td>82.4 (28/34)</td>
<td></td>
</tr>
<tr>
<td>length of duration of the disease (years)</td>
<td>13 (15.6)</td>
<td>17 (22.0)</td>
<td>0.08</td>
</tr>
<tr>
<td>CRP mg/l, median (mean)</td>
<td>3.2 (8.1)</td>
<td>4.95 (8.5)</td>
<td>0.24</td>
</tr>
<tr>
<td>BASDAI, median (mean)</td>
<td>20.0 (19.8)</td>
<td>35.8 (37.2)</td>
<td>0.00047</td>
</tr>
</tbody>
</table>
Tab. 2: Representation of the individual TNFα inhibitors.

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>Days/Average Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infliximab (5 mg/kg à 6 weeks)</td>
<td>2</td>
</tr>
<tr>
<td>Adalimumab (40 mg à 2 weeks)</td>
<td>14</td>
</tr>
<tr>
<td>Etanercept (50 mg à 1 week)</td>
<td>3</td>
</tr>
<tr>
<td>Golimumab (50 mg à 1month)</td>
<td>2</td>
</tr>
</tbody>
</table>

In patients treated with TNFα inhibitors, a significantly lower VEGF level was found in comparison with the untreated patients (140.3 (109.4; 262.2) vs. 261 (172.4; 396.6) pg/ml; p = 0.02) (Figure 1).

No difference was found between the BMP-2 levels in both groups (treated vs. untreated patients) (254.8 (230.1; 267.3) vs. 261.1 (248.6; 273.5) pg/ml; p = 0.24) (Figure 2).

Fig. 1: Box plot graph, levels of VEGF (pg/ml) in patients treated and not treated with TNFα inhibitors (VEGF = Vascular Endothelial Growth Factor, TNF = Tumour Necrosis Factor).

Fig. 2: Box plot graph, levels of BMP-2 (pg/ml) in patients treated and not treated with TNFα inhibitors (BMP = Bone Morphogenic Protein, TNF = Tumour Necrosis Factor).

Fig. 3: Relationship between VEGF (pg/ml) and CRP (mg/l) (VEGF = Vascular Endothelial Growth Factor, CRP = C-reactive protein), correlation analysis, \( r = 0.56; p = 0.00001 \).

Fig. 4: Relationship VEGF (pg/ml) and BASDAI (VEGF = Vascular Endothelial Growth Factor, BASDAI = Bath ankylosing spondylitis disease activity index), correlation analysis, \( r = 0.33; p = 0.015 \).
A correlation analysis did not reveal a relationship between VEGF and BMP-2 ($r = 0.057; p = 0.68$).

Serum levels of VEGF correlated with serum levels of CRP ($r = 0.56; p = 0.00001$) and the BASDAI value ($r = 0.33; p = 0.015$) (Figure 3, resp. 4). A mild correlation between BMP-2 and CRP ($r = 0.28; p = 0.036$) and even no correlation between BMP-2 and BASDAI ($r = 0.056, p = 0.68$) were found (Figures 5 and 6).

**Discussion**

It is difficult to know whether TNFα inhibitors influence radiographic progression in patients suffering from AS. This issue is being intensively investigated but important limitations exist. One of them is the fact that ossification in the region of longitudinal ligaments is a very slow process, often lasting many years. Due to ethical reasons therefore there cannot be placebo-controlled, randomized studies with TNFα inhibitors, although such studies would demonstrate the possible effect on the radiographic progression. In such patients one key problem is how to determine the radiographic progression itself. At present, determining a change in the mSASSS spinal score (modified Stokes ankylosing spondylitis spinal score) is considered valid. This score evaluates changes in lateral x-rays of the lumbar and cervical spine by means of a scoring system (14).

One of the possibilities of how to evaluate the effect of the treatment on radiographic progression is to determine the predictors of radiographic progression and to monitor whether these markers are influenced by therapy. Determining the predictors of radiographic progression is a considerably complex process and requires monitoring the spinal score at sufficiently long-term time intervals. The first data in this respect already exist. For example, a predictive effect on radiographic progression in CRP and ESR (erythrocytes sedimentation rate) was demonstrated in this way (15). Another predictor of radiographic progression is then the extent of the already present radiographic changes themselves at the beginning of monitoring (15).

VEGF is a signal protein which plays a role in the regulation of angiogenesis and has an irreplaceable role in inflammatory processes generally. In patients suffering from AS (8) or spondyloarthritis (9, 16), increased VEGF levels in comparison with control groups of healthy subjects was demonstrated and these levels correlated with clinical (BASDAI) (9) and laboratory (8, 9) markers of activity. Also, in our group of patients the VEGF levels correlated with the BASDAI and CRP levels.

The latest data have also demonstrated a predictive effect of VEGF on radiographic progression in patients with spondyloarthritis. Poddubnyy et al. (10) carried out an analysis of 172 patients with axial spondyloarthritis in which they evaluated whether VEGF predicted radiographic progression during a two year period of monitoring. They have demonstrated that patients with greater radiographic progression ($\geq 2$ mSASSS units) possessed significantly higher VEGF levels versus the group of patients without radiographic progression. The same occurred when they evaluated the development of new syndesmophytes. Similar data demonstrating the predictive effect of the VEGF level on radiographic progression were also published earlier in a study involving a group of 52 patients with a definite diagnosis of AS (17).
The present authors' evaluation has demonstrated significantly lower serum VEGF levels in patients treated with TNFα inhibitors versus the untreated patients. These data are in accordance with the data of other authors in whose studies the administration of TNFα inhibitors resulted in a decrease in the VEGF level (16, 18, 19, 20, 21). For the time being it is not clear whether TNFα inhibitors influence radiographic progression in patients with AS. Nevertheless, as shown by our data, in patients who underwent the treatment the VEGF level, an important predictor of radiographic progression, was significantly lower.

Besides regulation of angiogenesis and pathogenesis of inflammatory changes, VEGF plays simultaneously a key role in the process of enchondral ossification (22, 23). It is not therefore quite clear in which part of the complex process of ossification in patients with AS it exerts its principal influence, whether it is in the development of advanced lesions, or as late as the process of enchondral ossification itself. The serum level of VEGF then may include both of these components and the predictive effect of VEGF on radiographic progression may be a manifestation of the first or the second, or the sum total of both phenomena. In our patients, the VEGF level did not correlate with BMP-2, which participates in the regulation of bone proliferation, and in patients with AS its level correlated with the spinal score (11). However, the predictive influence on radiographic progression has not been determined in this protein.

The question arises as to why, in the two-year studies with TNFα inhibitors, no impact on radiographic progression occurs. In this context the “TNF brake theory” (TNF brake) is mentioned, which states that TNFα acts by way of Dickkopf-1 as the inhibitor of osteoproduction; and suppression of inflammation thus, on the other hand, may start the osteoproduction changes. However, another explanation may be the theory of early and advanced lesions. As mentioned in the introduction, TNFα inhibitors favourably influence the inflammatory changes in the region of vertebral corners. In the case of an early lesion there occurs disappearance ad integrum; but it is the lesion alone which, without treatment, would develop in a syndesmophyte after a much longer period than two years. In the case of an advanced lesion osteoproduction changes probably occur independently of the activity of inflammation. On the other hand, through the mechanism of the TNF brake, osteoproduction processes may be accelerated by treatment. It would thus mean that in this respect the benefit for the patient would be primarily the early onset of therapy, which is in accordance with the latest results. Baraliakos et al. published eight-year data of patients with AS, comparing the development of the spinal score over the course of eight years in patients treated with infliximab in comparison with an untreated cohort. At the beginning, both groups did not significantly differ in the parameter of the spinal score. Patients treated with TNFα inhibitors showed, after eight years, a significantly lower change in the spinal score than the untreated patients, and the change in the spinal score in the first four years was similar; on the other hand, it was more expressed between the fourth and eighth years of monitoring. The number of syndesmophytes after eight years was significantly lower in treated versus untreated patients, though the numbers of syndesmophytes at the beginning of monitoring were similar (24). Another analysis performed by Haroon et al. found that patients with a later onset of therapy (>10 years) showed a greater risk of radiographic progression than patients with an early onset of treatment. Radiographic progression was then lower in the patients treated with TNFα inhibitors, if the time period between the compared pictures was more than 3.9 years (25).

When discussing the possible favourable influence of treatment with TNFα inhibitors on radiographic progression, it is relevant to mention the recent evidence of the positive effect of non-steroidal anti-inflammatory drugs (NSA): the conventional treatment of patients with AS. There is one randomised study and a few other studies showing evidence that taking NSA continuously or in higher doses favourably affects the spinal radiographic progression in these patients (26, 27, 28, 29).

Conclusion

VEGF most probably plays a role in the pathogenesis of the development of osteoproduction changes in patients suffering from AS as it has been recently discovered to be a predictive biomarker of radiographic progression in these patients. The present authors’ analysis found that in patients treated with TNFα inhibitors there was a significantly lower level of VEGF than in untreated patients, which was in accordance with some hitherto published analyses. This finding contributes to other evidence of the positive effect of TNFα inhibitors on radiographic progression in patients suffering from AS. The amount of evidence has been on the increase recently. The present study did not demonstrate any effect on the BMP-2 level during treatment with TNFα inhibitors or a correlation with VEGF levels.

References


Supported by the Ministry of Health of the Czech Republic – RVO (FNHK, 00179906).

Received: 09/05/2014 Accepted in revised form: 23/06/2014

Corresponding author:

MUDr. Marian Tošovský, 2nd Internal Gastroenterological Department, University Hospital, Sokolská 581, 500 05, Hradec Králové, Czech Republic; email: tosmar@post.cz